Top

Published in:

Open Access 01-08-2018 | Original Article

Synergistic effect of TRAIL and irradiation in elimination of glioblastoma stem-like cells

Authors: Junfeng Liu, Qinglei Gao, Tao Xie, Yu Liu, Longjun Luo, Cheng Xu, Lu Shen, Feng Wan, Ting Lei, Fei Ye

Published in: Clinical and Experimental Medicine | Issue 3/2018

Abstract

Glioblastoma multiforme (GBM) is the most common malignancy in central nervous system. A small subpopulation of GBM cells known as GBM stem-like cells (GSLCs) were supposed to be the most malignant cells among GBM cells as they are resistant to multiple therapies including radiotherapy. In this study, we set up two GSLCs cell lines from the two parental U87 and U251 glioma cell lines, and studied the expression of apoptosis-related genes alteration in GSLCs before and after irradiation. We found that one of the receptors of TNF-related apoptosis-inducing ligand (TRAIL), DR5, was dramatically up-regulated in GSLCs after irradiation (IR). Although GSLCs are resistant to both TRAIL and radiation treatment alone, the combined treatment with TRAIL and irradiation achieved maximum killing effect of GSLCs due to inducing the expression of DR5 and inhibiting the expression of cFLIP. Therefore, TRAIL and IR combined treatment would be a simple but practical therapeutic strategy for clinical application.

Available only for authorised users

Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359(5):492–507.CrossRefPubMed

Bao SD, Wu QL, McLendon RE, Hao YL, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444(7120):756–60.CrossRefPubMed

Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer. 2006;5:67.CrossRefPubMedPubMedCentral

Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105–11.CrossRefPubMed

Ortensi B, Setti M, Osti D, Pelicci G. Cancer stem cell contribution to glioblastoma invasiveness. Stem Cell Res Ther. 2013;4(1):18.CrossRefPubMedPubMedCentral

Schulenburg A, Blatt K, Cerny-Reiterer S, Sadovnik I, Herrmann H, Marian B, et al. Cancer stem cells in basic science and in translational oncology: can we translate into clinical application? J Hematol Oncol. 2015;8:16.CrossRefPubMedPubMedCentral

Wang J, Wakeman TP, Lathia JD, Hjelmeland AB, Wang XF, White RR, et al. Notch promotes radioresistance of glioma stem cells. Stem Cells. 2010;28(1):17–28.PubMedPubMedCentral

Kim Y, Kim KH, Lee J, Lee YA, Kim M, Lee SJ, et al. Wnt activation is implicated in glioblastoma radioresistance. Lab Invest. 2012;92(3):466–73.CrossRefPubMed

Santoni M, Burattini L, Nabissi M, Morelli MB, Berardi R, Santoni G, et al. Essential role of Gli proteins in glioblastoma multiforme. Curr Protein Pept Sci. 2013;14(2):133–40.CrossRefPubMed

10.

Kim SH, Ezhilarasan R, Phillips E, Gallego-Perez D, Sparks A, Taylor D, et al. Serine/threonine kinase MLK4 determines mesenchymal identity in glioma stem cells in an NF-kappaB-dependent manner. Cancer Cell. 2016;29(2):201–13.CrossRefPubMedPubMedCentral

11.

Verheij M, Bartelink H. Radiation-induced apoptosis. Cell Tissue Res. 2000;301(1):133–42.CrossRefPubMed

12.

Fulda S. Inhibitor of apoptosis (IAP) proteins as therapeutic targets for radiosensitization of human cancers. Cancer Treat Rev. 2012;38(6):760–6.CrossRefPubMed

13.

Shinomiya N. New concepts in radiation-induced apoptosis: ‘premitotic apoptosis’ and ‘postmitotic apoptosis’. J Cell Mol Med. 2001;5(3):240–53.CrossRefPubMed

14.

Senbabaoglu F, Cingoz A, Kaya E, Kazancioglu S, Lack NA, Acilan C, et al. Identification of Mitoxantrone as a TRAIL-sensitizing agent for Glioblastoma Multiforme. Cancer Biol Ther. 2016;17(5):546–57.CrossRefPubMedPubMedCentral

15.

Prasad S, Kim JH, Gupta SC, Aggarwal BB. Targeting death receptors for TRAIL by agents designed by Mother Nature. Trends Pharmacol Sci. 2014;35(10):520–36.CrossRefPubMed

16.

Yu CC, Chiou GY, Lee YY, Chang YL, Huang PI, Cheng YW, et al. Medulloblastoma-derived tumor stem-like cells acquired resistance to TRAIL-induced apoptosis and radiosensitivity. Childs Nerv Syst. 2010;26(7):897–904.CrossRefPubMed

17.

Henrich CJ, Brooks AD, Erickson KL, Thomas CL, Bokesch HR, Tewary P, et al. Withanolide E sensitizes renal carcinoma cells to TRAIL-induced apoptosis by increasing cFLIP degradation. Cell Death Dis. 2015;6:e1666.CrossRefPubMedPubMedCentral

18.

Dao P, Smith N, Scott-Algara D, Garbay C, Herbeuval JP, Chen H. Restoration of TRAIL-induced apoptosis in resistant human pancreatic cancer cells by a novel FAK inhibitor, PH11. Cancer Lett. 2015;360(1):48–59.CrossRefPubMed

19.

Alexiou GA, Tsamis KI, Vartholomatos E, Peponi E, Tzima E, Tasiou I, et al. Combination treatment of TRAIL, DFMO and radiation for malignant glioma cells. J Neurooncol. 2015;123(2):217–24.CrossRefPubMed

20.

Wu X, Lippman SM. An intermittent approach for cancer chemoprevention. Nat Rev Cancer. 2011;11(12):879–85.CrossRefPubMed

21.

Abdulghani J, El-Deiry WS. TRAIL receptor signaling and therapeutics. Expert Opin Ther Target. 2010;14(10):1091–108.CrossRef

22.

Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 1999;104(2):155–62.CrossRefPubMedPubMedCentral

23.

Ding L, Yuan C, Wei F, Wang G, Zhang J, Bellail AC, et al. Cisplatin restores TRAIL apoptotic pathway in glioblastoma-derived stem cells through up-regulation of DR5 and down-regulation of c-FLIP. Cancer Invest. 2011;29(8):511–20.CrossRefPubMedPubMedCentral

24.

Xiao QG, Tan YH, Guo Y, Yang HK, Mao F, Xie RF, et al. Soluble LRIG2 ectodomain is released from glioblastoma cells and promotes the proliferation and inhibits the apoptosis of glioblastoma cells in vitro and in vivo in a similar manner to the full-length LRIG2. PLoS One. 2014;9(10):e111419.CrossRefPubMedPubMedCentral

25.

Kim SM, Oh JH, Park SA, Ryu CH, Lim JY, Kim DS, et al. Irradiation enhances the tumor tropism and therapeutic potential of tumor necrosis factor-related apoptosis-inducing ligand-secreting human umbilical cord blood-derived mesenchymal stem cells in glioma therapy. Stem Cells. 2010;28(12):2217–28.CrossRefPubMed

26.

Capper D, Gaiser T, Hartmann C, Habel A, Mueller W, Herold-Mende C, et al. Stem-cell-like glioma cells are resistant to TRAIL/Apo2L and exhibit down-regulation of caspase-8 by promoter methylation. Acta Neuropathol. 2009;117(4):445–56.CrossRefPubMed

27.

Geismann C, Grohmann F, Sebens S, Wirths G, Dreher A, Hasler R, et al. c-Rel is a critical mediator of NF-kappaB-dependent TRAIL resistance of pancreatic cancer cells. Cell Death Dis. 2014;5:e1455.CrossRefPubMedPubMedCentral

28.

Kazimirsky G, Jiang W, Slavin S, Ziv-Av A, Brodie C. Mesenchymal stem cells enhance the oncolytic effect of Newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL. Stem Cell Res Ther. 2016;7(1):149.CrossRefPubMedPubMedCentral

29.

Im CN, Yun HH, Song B, Youn DY, Cui MN, Kim HS, et al. BIS-mediated STAT3 stabilization regulates glioblastoma stem cell-like phenotypes. Oncotarget. 2016;7(23):35056–70.CrossRefPubMedPubMedCentral

30.

Rosa P, Sforna L, Carlomagno S, Mangino G, Miscusi M, Pessia M, et al. Overexpression of large-conductance calcium-activated potassium channels in human glioblastoma stem-like cells and their role in cell migration. J Cell Physiol. 2017;232(9):2478–88.CrossRefPubMed

31.

Oh SJ, Yang JI, Kim O, Ahn EJ, Kang WD, Lee JH, et al. Human U87 glioblastoma cells with stemness features display enhanced sensitivity to natural killer cell cytotoxicity through altered expression of NKG2D ligand. Cancer Cell Int. 2017;17:22.CrossRefPubMedPubMedCentral

32.

Choy W, Nagasawa DT, Trang A, Thill K, Spasic M, Yang I. CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme. Neurosurg Clin N Am. 2012;23(3):391.CrossRefPubMed

33.

Grosse-Gehling P, Fargeas CA, Dittfeld C, Garbe Y, Alison MR, Corbeil D, et al. CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges. J Pathol. 2013;229(3):355–78.CrossRefPubMed

34.

Ramasamy S, Narayanan G, Sankaran S, Yu YH, Ahmed S. Neural stem cell survival factors. Arch Biochem Biophys. 2013;534(1–2):71–87.CrossRefPubMed

35.

Schlegel CR, Fonseca AV, Stocker S, Georgiou ML, Misterek MB, Munro CE, et al. DAPK2 is a novel modulator of TRAIL-induced apoptosis. Cell Death Differ. 2014;21(11):1780–91.CrossRefPubMedPubMedCentral

36.

Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, et al. Inhibition of death receptor signals by cellular FLIP. Nature. 1997;388(6638):190–5.CrossRefPubMed

37.

Lacour S, Hammann A, Wotawa A, Corcos L, Solary E, Dimanche-Boitrel MT. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res. 2001;61(4):1645–51.PubMed

38.

Flusberg DA, Sorger PK. Surviving apoptosis: life-death signaling in single cells. Trends Cell Biol. 2015;25(8):446–58.CrossRefPubMedPubMedCentral

39.

Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov. 2009;8(1):33–40.CrossRefPubMedPubMedCentral

Title: Synergistic effect of TRAIL and irradiation in elimination of glioblastoma stem-like cells
Authors: Junfeng Liu
Qinglei Gao
Tao Xie
Yu Liu
Longjun Luo
Cheng Xu
Lu Shen
Feng Wan
Ting Lei
Fei Ye
Publication date: 01-08-2018
Publisher: Springer International Publishing
Published in: Clinical and Experimental Medicine / Issue 3/2018
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI: https://doi.org/10.1007/s10238-018-0504-7

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Synergistic effect of TRAIL and irradiation in elimination of glioblastoma stem-like cells

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2018

The role of the alternative pathway of complement activation in glomerular diseases

The complex alteration in the network of IL-17-type cytokines in patients with hereditary angioedema

Reduced mitochondrial DNA content in lymphocytes is associated with insulin resistance and inflammation in patients with impaired fasting glucose

The humoral immunity to epidermal and dermal antigens in psoriasis: a downstream rather than an upstream event

Is the 1298A>C polymorphism in the MTHFR gene a risk factor for arterial ischaemic stroke in children? The results of meta-analysis

Droplet digital PCR detects high rate of TP53 R249S mutants in cell-free DNA of middle African patients with hepatocellular carcinoma

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page